Skip to main content

Table 1 Summary of metabolite concentrations in brainstem after sildenafil, CGRP and placebo

From: Effects of sildenafil and calcitonin gene-related peptide on brainstem glutamate levels: a pharmacological proton magnetic resonance spectroscopy study at 3.0 T

 

Baseline

Scan 1

Scan 2

Mean mmol/L

SD

Mean mmol/L

SD

% change from baseline

P

Mean mmol/L

SD

% change from baseline

P

Glutamate

 Sildenafil

7.77

0.65

8.21

0.53

5.6

0.039*

8.06

0.77

3.7

0.101

 CGRP

7.92

1.11

7.49

0.88

−5.4

0.639

8.08

0.73

−2.0

0.228

 Placebo

7.96

0.50

7.72

0.61

−3.0

–

7.70

0.65

−3.3

–

Lactate

 Sildenafil

0.90

0.21

0.45

0.41

−50.0

0.017*

0.43

0.33

− 51.9

0.156

 CGRP

0.71

0.51

0.49

0.44

−30.9

0.151

0.42

0.41

−40.6

0.494

 Placebo

0.75

0.65

0.89

0.68

21.6

–

0.62

0.42

−15.6

–

NAA

 Sildenafil

7.73

0.79

7.93

0.79

2.8

0.236

7.95

0.69

3.0

0.370

 CGRP

7.58

0.72

7.56

0.68

−0.2

0.821

8.06

0.82

6.3

0.127

 Placebo

7.61

0.63

7.64

0.58

0.4

–

7.73

0.72

1.6

–

Total creatine

 Sildenafil

4.25

0.35

4.33

0.32

1.0

0.978

4.23

0.28

−0.3

0.735

 CGRP

4.38

0.38

4.39

0.53

0.03

0.562

4.50

0.33

2.7

0.170

 Placebo

4.24

0.33

4.33

0.47

2.0

–

4.21

0.32

−0.7

–

  1. *P<0.05. P values reported for delta change from baseline to scan 1 and 2 after sildenafil and CGRP, compared to the corresponding change from baseline after placebo
  2. NAA N-Acetylaspartate, SD standard deviation
Back to article page

The Journal of Headache and Pain

ISSN: 1129-2377

Contact us